layoffs
Merck Moves All R&D Operations Out of UK, Citing Unfavorable Environment
Merck; MSD; R&D relocation; UK life sciences; drug discovery; Brexit impact; London Bioscience Innovation Centre; Francis Crick Institute; government investment; layoffs
Novo Nordisk to Cut 9,000 Jobs Globally as New CEO Targets $1.3B Savings by 2026
Novo Nordisk; layoffs; 9000 jobs; cost savings; CEO Doustdar; restructuring; weight-loss drugs; Wegovy; Ozempic; competition; Eli Lilly; profit guidance
AC Immune Narrows Pipeline and Cuts 30% Workforce to Extend Cash Runway
AC Immune; pipeline reduction; layoffs; cash runway; biotech; Alzheimer’s disease; Parkinson’s disease; late-stage assets; workforce reduction
Exelixis to Lay Off 130 Employees, Shut Down Pennsylvania Site in Post-Pandemic Downsizing
Exelixis; layoffs; Pennsylvania site closure; post-pandemic downsizing; biotech reorganization; Alameda headquarters; zanzalintinib; cabozantinib; King of Prussia
Exelixis Closes Pennsylvania Site, Cuts 130 Jobs in Major Restructuring
Exelixis; layoffs; Pennsylvania; King of Prussia; biotech; job cuts; site closure; restructuring; Alameda Headquarters; cancer drugs
CNS Pharmaceuticals Pursues Public Offering to Fund Phase 2 GBM Trial After Cost Cuts
CNS Pharmaceuticals; biotech; layoffs; IPO; public offering; phase 2 trial; glioblastoma multiforme; funding; cash position
Merck Begins Layoffs in New Jersey as Part of $3 Billion Cost-Cutting Plan
Merck & Co.; New Jersey; layoffs; pharma industry; cost-cutting; Keytruda; restructuring; WARN notice
Bicycle Therapeutics Lays Off 25% of Workforce After Genentech Collaboration Ends
Bicycle Therapeutics; layoffs; Genentech; R&D partnership; biotech; cost reduction; workforce reduction; strategic realignment
BioNTech to Cut 90 More US Jobs Amid Strategic Realignment
BioNTech; layoffs; job cuts; R&D; pipeline focus; Gaithersburg; Cambridge; cell therapy; post-COVID market; strategic alignment
Bayer Layoffs Top 12,000 with More Cuts Expected Amid Ongoing Restructuring
Bayer; layoffs; restructuring; cost-cutting; employee reductions; Bill Anderson; 2025; pharma industry